Literature DB >> 2797931

Clinical characteristics of respiratory syncytial virus infections in healthy versus previously compromised host.

K Meert1, S Heidemann, M Lieh-Lai, A P Sarnaik.   

Abstract

In an effort to delineate the clinical characteristics of respiratory syncytial virus (RSV) infection in the compromised host, we compared children with bronchopulmonary dysplasia (BPD), congenital heart disease (CHD), premature birth, failure to thrive, and gastroesophageal reflux to previously healthy children. During a four-year period, 262 patients were admitted to the hospital with RSV infection diagnosed by a rapid RSV antigen detection test. Children with BPD or CHD had more hospital days and supplemental oxygen days than the previously healthy group (P less than 0.05). Patients with BPD also had more ICU days, ventilator days, and NPO days, as well as a higher physiologic stability index and therapeutic intervention score than the previously healthy group (P less than 0.05). Premature infants were more likely to present with apnea from RSV (P less than 0.001). Patients with underlying illness tended to be older, although significant difference was demonstrated only for the BPD group (7.0 +/- 5.3 vs. 3.5 +/- 3.3, P less than 0.05). Patients with BPD and CHD had more nosocomial infections than the previously healthy group (P less than 0.0001) and death occurred only in patients with underlying illness. We conclude that previously compromised patients are at risk for more severe and prolonged RSV disease. Earlier diagnosis and therapeutic intervention may be necessary in such patients to improve outcome.

Entities:  

Mesh:

Year:  1989        PMID: 2797931     DOI: 10.1002/ppul.1950070309

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  12 in total

Review 1.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort.

Authors:  S J Clark; M W Beresford; N V Subhedar; N J Shaw
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

3.  Health Care and Societal Costs of Bronchopulmonary Dysplasia.

Authors:  Wannasiri Lapcharoensap; Henry C Lee; Amy Nyberg; Dmitry Dukhovny
Journal:  Neoreviews       Date:  2018-04

Review 4.  Respiratory syncytial virus infection in children with congenital heart disease: a review.

Authors:  D E Fixler
Journal:  Pediatr Cardiol       Date:  1996 May-Jun       Impact factor: 1.655

Review 5.  Bronchiolitis. Origins and optimal management.

Authors:  M L Everard
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

6.  Risk factors for mechanical ventilation in respiratory syncytial virus infection.

Authors:  W J Tissing; H A van Steensel-Moll; M Offringa
Journal:  Eur J Pediatr       Date:  1993-02       Impact factor: 3.183

Review 7.  Best practice in the prevention and management of paediatric respiratory syncytial virus infection.

Authors:  Simon B Drysdale; Christopher A Green; Charles J Sande
Journal:  Ther Adv Infect Dis       Date:  2016-02-10

8.  Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands.

Authors:  Barbara Whelan; Elles Musters; Amanda Murray; Eilish Moore; Lenie Lievaart; Sjoerd Visser; Esther Toxopeus; Annemarie van Veen; Gerard Notario; Fiona J Campbell
Journal:  Drugs Ther Perspect       Date:  2016-01-26

9.  Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.

Authors:  John P DeVincenzo; Christopher S Ambrose; Doris Makari; Leonard B Weiner
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

Review 10.  Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.

Authors:  Josephine Mauskopf; Andrea V Margulis; Miny Samuel; Kathleen N Lohr
Journal:  Pediatr Infect Dis J       Date:  2016-07       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.